申请人:Berwaer Monique Jenny Marie
公开号:US20080194656A1
公开(公告)日:2008-08-14
The present invention relates to a group of benzotriazole derivatives, infra that are potent cannabinoid-CB
1
modulators (known as antagonists or inverse agonists), useful in the treatment obesity, psychiatric and neurological disorders, as well as other diseases involving cannabinoid-CB
1
neurotransmission (Current Opinion in Drug Discovery & Development 2004 7(4):498-506)
the pharmaceutically acceptable acid addition salts and stereoisomeric forms thereof,
wherein
R
1
is hydrogen, halo, trifluoromethyl, C
1-4
alkyl, C
1-4
alkyloxy- or C
1-4
alkyloxycarbonyl;
R
2
is hydrogen, phenyl, C
3-7
cycloalkyl or C
1-6
alkyl optionally substituted with Ar
1
;
R
3
is hydrogen, hydroxyl or C
1-6
alkyl;
Ar
1
is phenyl or phenyl substituted with up to three halo substituents; and
Het represents a monocyclic 5 or 6 membered partially saturated or aromatic heterocycle selected from furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyrimidinyl, pyridinyl, pyrazinyl, triazinyl, pyridazinyl, 2H-pyranyl or 4H-pyranyl wherein said heterocycle is optionally substituted with C
1-6
alkyl;
本发明涉及一组苯并三唑衍
生物,其为有效的
大麻素-CB1调节剂(也称为拮抗剂或反向激动剂),可用于治疗肥胖症、精神和神经疾病以及涉及
大麻素-CB1神经递质的其他疾病(《药物发现与开发的现状》2004年7(4):498-506),包括其药学上可接受的酸加合物盐和立体异构体形式。其中,R1为氢、卤素、三
氟甲基、C1-4烷基、C1-4烷氧基或C1-4烷氧羰基;R2为氢、苯基、C3-7环烷基或C1-6烷基,可选地取代Ar1;R3为氢、羟基或C1-6烷基;Ar1为苯基或取代了最多三个卤素基团的苯基;Het表示从
呋喃基、
噻吩基、
吡咯基、
噁唑基、
噻唑基、
咪唑基、
吡唑基、
异噁唑基、
异噻唑基、噁二唑基、三唑基、
噻二唑基、
嘧啶基、
吡啶基、
吡嗪基、三嗪基、
吡啶嗪基、
2H-吡喃基或
4H-吡喃基中选择的一个单环5或6成员部分饱和或芳香杂环,其中所述杂环可选地取代C1-6烷基。